These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 25381721

  • 1. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
    Qu J, Yu Z, Li Q, Chen Y, Xiang D, Tan L, Lei C, Bai W, Li H, Shang Q, Chen L, Hu X, Lu W, Li Z, Chen D, Wang X, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Chen G, Li Y, Zeng Z, Rong G, Dong Z, Chen Y, Lou M, Wang C, Lu Y, Zhang C, Yang Y.
    Trials; 2014 Nov 10; 15():438. PubMed ID: 25381721
    [Abstract] [Full Text] [Related]

  • 2. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X.
    Medicine (Baltimore); 2019 Apr 10; 98(17):e15297. PubMed ID: 31027094
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
    Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J.
    Trials; 2020 Jun 05; 21(1):482. PubMed ID: 32503608
    [Abstract] [Full Text] [Related]

  • 4. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y.
    J Hepatol; 2022 Dec 05; 77(6):1515-1524. PubMed ID: 35985545
    [Abstract] [Full Text] [Related]

  • 5. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Rong G, Chen Y, Yu Z, Li Q, Bi J, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chen Y, Dong Z, Bai W, Yoshida EM, Mendez-Sanchez N, Hu KQ, Qi X, Yang Y.
    J Infect Dis; 2022 Mar 15; 225(6):1091-1099. PubMed ID: 32437567
    [Abstract] [Full Text] [Related]

  • 6. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.
    Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG.
    Chin J Integr Med; 2018 Sep 15; 24(9):653-660. PubMed ID: 30209792
    [Abstract] [Full Text] [Related]

  • 7. Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial.
    Xing Y, Zhong W, Peng D, Han Z, Zeng H, Wang Y, Feng L, Huang J, Xu L, Chen M, Zhou D, Jiang K, Deng X, Zhou H, Tong G.
    Pharmacol Res; 2023 Apr 15; 190():106737. PubMed ID: 36940891
    [Abstract] [Full Text] [Related]

  • 8. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
    Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, Jiang Y, Long F, Lin H, He J, Wu Q, Zhang M, Wang L, Zhu X, Gong M, Sun X, Sun J, Sun F, Lu W, Xu W, Chen G, Li Z, Gan D, Yang X, Du H, Ye Y.
    Trials; 2020 Aug 12; 21(1):708. PubMed ID: 32787905
    [Abstract] [Full Text] [Related]

  • 9. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.
    World J Gastroenterol; 2015 Nov 21; 21(43):12421-9. PubMed ID: 26604649
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G, Viganò M, Loglio A, Lampertico P.
    Liver Int; 2017 Jan 21; 37 Suppl 1():45-51. PubMed ID: 28052621
    [Abstract] [Full Text] [Related]

  • 11. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet () and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial.
    Li ZX, Zhao ZM, Liu P, Zheng QS, Liu CH.
    Chin J Integr Med; 2021 Jul 21; 27(7):509-513. PubMed ID: 32572776
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies.
    Song Y, Zhao J, Wang S, Huang H, Hong J, Zuo J, Huo S.
    Medicine (Baltimore); 2019 May 21; 98(22):e15732. PubMed ID: 31145288
    [Abstract] [Full Text] [Related]

  • 13. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Gut; 2014 Dec 21; 63(12):1943-50. PubMed ID: 24615378
    [Abstract] [Full Text] [Related]

  • 14. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Wang PC, Wei TY, Tseng TC, Lin HH, Wang CC.
    Eur J Gastroenterol Hepatol; 2017 Aug 21; 29(8):946-950. PubMed ID: 28538267
    [Abstract] [Full Text] [Related]

  • 15. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH, C-TEAM study group and the Taiwan Liver Diseases Consortium.
    Liver Int; 2016 Dec 21; 36(12):1755-1764. PubMed ID: 27634134
    [Abstract] [Full Text] [Related]

  • 16. [Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses].
    Yang NH, Yuan GS, Zhou YC, Liu JW, Huang HP, Hu CG, Xiong L, Li Y, Zhou FY, Yang SL, Zhou YP.
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun 21; 36(6):775-9. PubMed ID: 27320877
    [Abstract] [Full Text] [Related]

  • 17. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y.
    Clin Exp Med; 2019 Aug 21; 19(3):309-320. PubMed ID: 31111345
    [Abstract] [Full Text] [Related]

  • 18. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P.
    J Hepatol; 2020 Nov 21; 73(5):1037-1045. PubMed ID: 32553667
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH, Kim BK, Kim JK, Kim HC, Kim DY, Park JY, Han KH, Kim SU, Shin SH, Hahn KY, Ahn SH.
    J Gastroenterol Hepatol; 2014 May 21; 29(5):1005-11. PubMed ID: 24325579
    [Abstract] [Full Text] [Related]

  • 20. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z.
    Gut Liver; 2020 Mar 15; 14(2):232-247. PubMed ID: 31158948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.